世界科学技术-中医药现代化
世界科學技術-中醫藥現代化
세계과학기술-중의약현대화
WORLD SCIENCE AND TECHNOLOGY-MODERNIZATION OF TRADITIONAL CHINESE MEDICINE
2014年
4期
811-816
,共6页
柔肝降酶合剂%药物性肝损害%基因表达%中医药疗法
柔肝降酶閤劑%藥物性肝損害%基因錶達%中醫藥療法
유간강매합제%약물성간손해%기인표체%중의약요법
Softening Liver and Reducing Enzyme Mixed Agent%drug-induced liver injury%gene expression%traditional Chinese medicine therapy
目的：观察柔肝降酶合剂治疗四氯化碳（CCl4）所致大鼠急性肝损伤的效果。方法：SD雄性大鼠60只，随机分成6组，分别为柔肝降酶合剂低、中、高3个剂量组、葡醛内酯组、正常组及模型组，采用CCl4腹腔注射致大鼠急性肝损伤模型，各中药组每日灌胃柔肝降酶合剂，正常组和模型组给予蒸馏水灌胃，葡醛内酯组灌胃葡醛内酯水溶液，于实验的第12天，禁食16澡后处死大鼠，检查肝组织病理学改变，测定大鼠血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST），肝组织匀浆测定大鼠肝组织超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、还原型谷胱甘肽（GSH）、过氧化氢酶（CAT）及丙二醛（MDA），RT-PCR法检测大鼠肝脏血红素氧化酶（HO-1）mRNA 表达水平。结果：与模型组比较，柔肝降酶合剂各剂量组大鼠肝病理损害均不同程度减轻，柔肝降酶合剂各剂量组及葡醛内酯组血清ALT及AST含量均明显降低（P<0.05或P<0.01）；柔肝降酶合剂各剂量组、葡醛内酯组肝匀浆GSH、GSH-Px、CAT、SOD含量明显升高（P<0.05或P<0.01），MDA含量明显降低（P<0.05或P<0.01）；各治疗组肝脏 HO-1 mRNA相对表达量明显升高（P<0.05或P<0.01）。结论：柔肝降酶合剂防治CCl4所致大鼠急性肝损伤疗效确切。
目的：觀察柔肝降酶閤劑治療四氯化碳（CCl4）所緻大鼠急性肝損傷的效果。方法：SD雄性大鼠60隻，隨機分成6組，分彆為柔肝降酶閤劑低、中、高3箇劑量組、葡醛內酯組、正常組及模型組，採用CCl4腹腔註射緻大鼠急性肝損傷模型，各中藥組每日灌胃柔肝降酶閤劑，正常組和模型組給予蒸餾水灌胃，葡醛內酯組灌胃葡醛內酯水溶液，于實驗的第12天，禁食16澡後處死大鼠，檢查肝組織病理學改變，測定大鼠血清丙氨痠氨基轉移酶（ALT）、天鼕氨痠氨基轉移酶（AST），肝組織勻漿測定大鼠肝組織超氧化物歧化酶（SOD）、穀胱甘肽過氧化物酶（GSH-Px）、還原型穀胱甘肽（GSH）、過氧化氫酶（CAT）及丙二醛（MDA），RT-PCR法檢測大鼠肝髒血紅素氧化酶（HO-1）mRNA 錶達水平。結果：與模型組比較，柔肝降酶閤劑各劑量組大鼠肝病理損害均不同程度減輕，柔肝降酶閤劑各劑量組及葡醛內酯組血清ALT及AST含量均明顯降低（P<0.05或P<0.01）；柔肝降酶閤劑各劑量組、葡醛內酯組肝勻漿GSH、GSH-Px、CAT、SOD含量明顯升高（P<0.05或P<0.01），MDA含量明顯降低（P<0.05或P<0.01）；各治療組肝髒 HO-1 mRNA相對錶達量明顯升高（P<0.05或P<0.01）。結論：柔肝降酶閤劑防治CCl4所緻大鼠急性肝損傷療效確切。
목적：관찰유간강매합제치료사록화탄（CCl4）소치대서급성간손상적효과。방법：SD웅성대서60지，수궤분성6조，분별위유간강매합제저、중、고3개제량조、포철내지조、정상조급모형조，채용CCl4복강주사치대서급성간손상모형，각중약조매일관위유간강매합제，정상조화모형조급여증류수관위，포철내지조관위포철내지수용액，우실험적제12천，금식16조후처사대서，검사간조직병이학개변，측정대서혈청병안산안기전이매（ALT）、천동안산안기전이매（AST），간조직균장측정대서간조직초양화물기화매（SOD）、곡광감태과양화물매（GSH-Px）、환원형곡광감태（GSH）、과양화경매（CAT）급병이철（MDA），RT-PCR법검측대서간장혈홍소양화매（HO-1）mRNA 표체수평。결과：여모형조비교，유간강매합제각제량조대서간병리손해균불동정도감경，유간강매합제각제량조급포철내지조혈청ALT급AST함량균명현강저（P<0.05혹P<0.01）；유간강매합제각제량조、포철내지조간균장GSH、GSH-Px、CAT、SOD함량명현승고（P<0.05혹P<0.01），MDA함량명현강저（P<0.05혹P<0.01）；각치료조간장 HO-1 mRNA상대표체량명현승고（P<0.05혹P<0.01）。결론：유간강매합제방치CCl4소치대서급성간손상료효학절。
This study was aimed to observe the effect of Softening Liver and Reducing Enzyme Mixed Agent (SLREXA) in the prevention of acute liver injury rats induced by carbon tetrachloride (CCl4). A total of 60 male SD rats were randomly divided into 6 groups, which were the SLREXA low-, middle-, high-dose group, glucurolactone group, normal group and model group. Intraperitoneal injection of CCl4 was used to induce acute liver injury rat mod-el. Intragastric administration of SLREXA was given to each Chinese medicine group. Intragastric administration of distilled water was given to the normal group and the model group. Intragastric administration of glucurolactone aque-ous solution was given to the glucurolactone group. On the 12th day of the experiment, after 16-hour fasting, rats were killed. Pathological changes in liver tissues were examined. Blood serum was determined for alanine aminotrans-ferase (ALT) and aspartate aminotransferase (AST). The liver homogenate was determined for superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione (GSH), catalase (CAT) and malondialdehyde (MDA) in liver tis-sues of rats. RT-PCR was used to detect the expression level of mRNA in liver heme oxygenase-1 (HO-1). The re-sults showed that in the microscopic examination of liver tissues, compared with the model group, different doses of SLREXA can alleviate pathological damages of liver in varying degrees. Levels of blood serum ALT and AST content in different doses of SLREXA groups and glucurolactone group were significantly lower than those of the model group (P < 0.05 or P < 0.01). Compared with the model group, contents of GSH-Px, GSH, SOD, CAT in the liver ho-mogenate were significantly increased, and MDA content was decreased significantly (P< 0.05 or P< 0.01) in differ-ent doses of SLREXA groups and glucurolactone group; compared with the model group, the HO-1 mRNA relative expression quantity in the normal group and each treatment group increased obviously, with statistical significance (P< 0.05 or P< 0.01). It was concluded that SLREXA can prevent CCl4-induced liver injury rats with definite thera-peutic effect.
